Starling Oncology, Inc. - Common Stock (STLN)

Oncology Institute (NASDAQ:STLN), referred to as Starling Oncology by executives during its earnings call, reported a second consecutive quarter of positive adjusted EBITDA as specialty pharmacy growth and stronger drug margins boosted third-quarter results. Chief Financial Officer Rob Carter said